Back to Journals » Medical Devices: Evidence and Research » Volume 3

Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis

Authors Rosa J, Sabelli M, Soriano E

Published 10 August 2010 Volume 2010:3 Pages 25—31

DOI https://doi.org/10.2147/MDER.S7504

Review by Single-blind

Peer reviewer comments 2


J Rosa1,2, M Sabelli1,2, Enrique R Soriano1,2
1Rheumatology Section, Internal Medical Services, Hospital Italiano de Buenos Aires, and Fundacion P.M. Catoggio para el progreso de la Reumatologia; 2University Institute, School of Medicine, Hospital Italiano de Buenos Aires, Argentina

Abstract: A new anti-tumor necrosis factor alpha (TNF-a) inhibitor with a novel mechanism of action has entered phase 3 trials in rheumatoid arthritis (RA). Certolizumab pegol (Cimzia®) is a humanized Fab' antibody fragment against TNF-a with a polyethylene glycol tail that prevents complement-dependent and antibody-dependent cell-mediated cytotoxicity or apoptosis. Four randomized clinical trials have been published so far. Reported results are similar to those published in previous studies with other TNF-a inhibitors, with ACR20, ACR50, and ACR70 responses of around 60%, 40%, and 20%, respectively, when combined with methotrexate and slightly lower when used as monotherapy. Safety was shown to be similar to that seen with TNF-a blockers and some cases of tuberculosis were seen in the trials, stressing the importance of a complete screening in these patients. Although we still need effectiveness and safety data in larger numbers of patients and longer follow-up, this new TNF inhibitor is a welcome addition to our current armamentarium for the treatment of RA.

Keywords: certolizumab pegol, rheumatoid arthritis therapy, biologic therapies

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]